Physician profile
Lucyann M Sciandra
NPI 1326096884
$2,075.70
in general payments reported to CMS, 2019-2025
15 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $18.46 · 2021: $116 · 2022: $217 · 2023: $108 · 2024: $126 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $430.97 | 2019-2025 | Biktarvy |
| Phathom Pharmaceuticals, INC. | $250.64 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $232.71 | 2019-2020 | |
| Amarin Pharma, INC. | $174.92 | 2019 | |
| Medtronic, INC. | $171.23 | 2025 | Symplicity G3 |
| Allergan, INC. | $134.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $122.09 | 2025 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $121.04 | 2022 | |
| Novo Nordisk INC | $115.97 | 2021 | |
| Ferring Pharmaceuticals INC. | $108.44 | 2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $80.97 | 2019 | |
| Astellas Pharma US INC | $69.99 | 2019 | |
| Emd Serono, INC. | $27.88 | 2019 | |
| Melinta Therapeutics, LLC | $22.72 | 2019 | |
| Insmed, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucyann Sciandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.